NCT01729871 - A Study Exploring Two Treatment Strategies in Patients With Atrial Fibrillation Who Undergo Catheter Ablation Therapy | Biotech Hunter

Enrollment

253

Participants

Timeline

Start Date

February 28, 2013

Primary Completion Date

October 31, 2014

Study Completion Date

October 31, 2014

Conditions

Atrial Fibrillation

Interventions

DRUG

rivaroxaban

rivaroxaban 20 mg orally, once-daily, administered preferably with the evening meal

DRUG

uninterrupted vitamin K antagonist (VKA)

dose-adjusted vitamin K antagonist (VKA) to achieve a recommended International Normalized Ratio (INR) of 2.0 to 3.0

Trial Locations (44)

Unknown

Beverly Hills

Los Angeles

Sacramento

San Francisco

Jacksonville

Maywood

Kansas City

Boston

Saint Louis Park

Ridgewood

Flushing

Durham

Columbus

Portland

Erie

Hershey

Philadelphia

Nashville

Austin

Dallas

Tyler

Charlottesville

Seattle

Tacoma

Aalst

Antwerp

Bruges

Genk

Hasselt

Brest

Montpellier

Pessac

Toulouse Cedex 9 N/A

Vandœuvre-lès-Nancy

Bad Krozingen

Bad Nauheim

Berlin

Dresden

Jena

Mönchengladbach

Neuwied

Bournemouth

Cottingham

London